|
|
British Journal of Cancer (2006) 95, 266-271.
doi:10.1038/sj.bjc.6603279 Published online 25 July 2006
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial
R Maggi1, A Lissoni2, F Spina1, M Melpignano3, P Zola4, G Favalli5, A Colombo6 and R Fossati7
1Clinica 'L. Mangiagalli', Università degli Studi di Milano, Milano, Italy
2Ospedale 'San Gerardo', Università degli Studi Milano 'Bicocca', Monza, Italy
3Azienda Ospedaliero-Universitaria di Parma, Università degli Studi di Parma, Italy
4Ospedale Mauriziano 'Umberto I', Università degli Studi di Torino, Italy
5Ospedali Civili di Brescia, Università degli Studi di Brescia, Italy
6Ospedale 'A. Manzoni', Lecco, Italy
7Department of Oncology, Istituto 'Mario Negri', Via Eritrea 62, 20157 Milano, Italy
Correspondence to: Dr R Fossati, E-mail: fossati@marionegri.it
This paper is dedicated to the memory of Dr Giuseppe Favalli who deceased last year.
This study was partially supported by grants from the National Research Council.
Received 16 March 2006; revised 19 June 2006; accepted 19 June 2006; published online 25 July 2006
Patients with high-risk endometrial carcinoma (stage IcG3, IIG3 with myometrial invasion >50%, and III) receive adjuvant therapy after surgery but it is not clear whether radiotherapy (RT) or chemotherapy (CT) is better. We randomly assigned 345 patients with high-risk endometrial carcinoma to adjuvant CT (cisplatin (50 mg m-2), doxorubicin (45 mg m-2), cyclophosphamide (600 mg m-2) every 28 days for five cycles, or external RT (45-50 Gy on a 5 days week-1 schedule). The primary end points were overall and progression-free survival. After a median follow-up of 95.5 months women in the CT group as compared with the RT group, had a no significant hazard ratio (HR) for death of 0.95 (95% confidence interval (CI), 0.66-1.36; P=0.77) and a nonsignificant HR for event of 0.88 (95% CI, 0.63-1.23; P=0.45). The 3, 5 and 7-year overall survivals were 78, 69 and 62% in the RT group and 76, 66 and 62% in the CT group. The 3, 5 and 7-year progression-free survivals were, respectively, 69, 63 and 56 and 68, 63 and 60%. Radiotherapy delayed local relapses and CT delayed metastases but these trends did not achieve statistical significance. Overall, both treatments were well tolerated. This trial failed to show any improvement in survival of patients treated with CT or the standard adjuvant radiation therapy. Randomised trials of pelvic RT combined with adjuvant cytotoxic therapy compared with RT alone are eagerly awaited.
Keywords: endometrial cancer; adjuvant therapy; randomised clinical trial; radiotherapy; chemotherapy
back to top  |
| Article links | |
| ||
| ||
 | Send to a friend | |
 | Download PDF | |
| ||
| ||
| ||
 | Full text | |
| ||
| ||
| ||
 | Preceding article | |
 | Next article | |
 | Table of Contents | |
| ||
| ||
| ||
| ||
| ||
|
|
|
|
| |||
| Print ISSN: 0007-0920 | Online ISSN: 1532-1827 | © 2006 Cancer Research UK | ||
| |||
| Privacy Policy | |||